QQQ $ 482.90 $ 3.01 (0.63 %)
DIA $ 391.33 $ 0.49 (0.13 %)
SPY $ 545.53 $ 1.79 (0.33 %)
TLT $ 90.38 $ -0.29 (-0.33 %)
GLD $ 215.23 $ -0.04 (-0.02 %)
$ 0.005
-- x --
-- x --
-- - --
$ 0.00 - $ 0.01
740
na
na
nm
na
TBD
na
na (na)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 psyched-colorado-legalizes-psychedelics-nyc-treats-alcoholism-with-ketamine-30m-series-a-for-startup

Colorado Voters Approve Initiative To Legalize And Regulate Psychedelics

 psychedelics-investment-holder-blackhawk-growth-hosts-meeting-for-potential-subsidiary-spin-out

Blackhawk Growth Corp. (OTCMKTS: BLRZF), an investment holding company focused on acquiring and developing high-growth companie...

 lsd-microdosing-yields-positive-outcomes-in-phase-1-study-more-trials-on-depression--existential-distress

Holding company Blackhawk Growth Corp.(OTC: BLRZF)'s subsidiary company MindBio Therapeutics Pty Ltd shared the positive da...

 recap-blackhawk-growth-funds-most-recent-business-highlights-from-retail-sales-to-phase-2-clinical-trials

Blackhawk Growth Corp.

 new-zealand-government-grants-650k-for-lsd-microdosing-trials

Mindbio Therapeutics, a subsidiary of cannabis and psychedelics holding company Blackhawk Growth Corp.

 psyched-protesters-at-dea-hq-demand-access-to-psychedelics-connecticut-approves-budget-bill-with-mdma--psilocybin-programs

Psychedelics policy action took center stage this week. 

Core News & Articles

   Successful completion of Phase 1 Clinical Trials 

 the-worlds-largest-microdosing-clinical-trial-has-been-completed-here-are-the-results

Mindbio Therapeutics, a company of the Blackhawk Growth Corp. (OTCPK: BLRZF) announced the completion of the world’s largest Ph...

Core News & Articles

   Co-Founder Justin Hanka to Deliver Keynote Address

Core News & Articles

  Phase 1 development of new digital therapeutic platform underway